Date: 2011-09-23
Type of information: Subvention
Company: CellMedica (UK)
Investors: the Wellcome Trust (UK)
Amount:
Funding type: subvention
Planned used:
Others: Cell Medica has announced that it has received further funding from the Wellcome Trust for its randomised controlled study to investigate the use of Cytovir CMV in combination with conventional antiviral drug therapy for the reduction of cytomegalovirus (CMV) infection in patients following allogeneic haematopoietic stem cell (bone marrow) transplantation (the CMV~IMPACT Study).
The Wellcome Trust has supported both the product development and the clinical research leading to the launch of theCMV~IMPACT Study in 2008. The trial is focussing on patients receiving a transplant from a sibling donor. The number of participating centres now includes 14 of the largest bone marrow transplantation sites across the UK to ensure achievement of patient recruitment targets. Independent assessment of data for safety considerations has to date confirmed no expected or unexpected serious adverse events associated with the cell therapy. An interim review has shown the original statistical assumptions in the design of the study are also consistent with the results to date. The study is on track for last patient recruitment at the end of 2012.
Therapeutic area: Infectious diseases
